Dr. Vijay Modur has assumed the role of Chief Medical Officer (CMO) at BPGbio, an AI-powered biopharma company based in Massachusetts. His primary responsibility is to advance the company’s ongoing clinical trials. Dr. Modur expressed his excitement about joining BPGbio and highlighted the transformative role of artificial intelligence in traditional drug discovery. He commended the company for being a pioneer in utilizing AI to leverage the potential of biology.
He further emphasized his enthusiasm for BPGbio’s extensive therapeutics and diagnostic pipeline, particularly those in late clinical development stages. Dr. Modur is eager to collaborate with the BPGbio team to progress and commercialize their pipeline, with a strong commitment to assisting patient communities facing unmet medical needs.
Niven R Narain, the CEO and President of BPGbio, expressed his deep respect and privilege in welcoming Dr. Modur to the company. He underlined Dr. Modur’s expertise in clinical development within the biotechnology and pharmaceutical industries, with a particular focus on oncology and rare diseases. BPGbio currently boasts five AI-guided therapeutic assets at various stages of development, with potential expansion considerations to a Phase 3 asset. Dr. Modur’s inclusion in the leadership team is expected to expedite the translational medicine focus necessary for advancing clinical assets and addressing the unmet needs of patients and their families.
Dr. Modur’s distinguished career has spanned multiple influential institutions, where he orchestrated strategic initiatives that have elevated the development of therapies for rare and complex diseases. Prior to joining BPGbio, he held the position of Head of Research and Development at Eloxx Pharmaceuticals. Throughout his career, Dr. Modur has assumed various leadership roles at esteemed organizations such as Zikani Therapeutics, Sanofi-Genzyme, HTG Molecular Diagnostics, Novartis Diagnostics, Novartis Oncology, and Merck & Co.
Dr. Modur’s educational background includes an MBBS degree from Karnatak University, Dharwad, India, and a PhD in experimental pathology from the University of Utah. His residency training was successfully concluded in the Department of Pathology and Laboratory Medicine at Washington University in St. Louis.
